Page last updated: 2024-10-26

ebselen and Hearing Loss

ebselen has been researched along with Hearing Loss in 3 studies

ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.

Hearing Loss: A general term for the complete or partial loss of the ability to hear from one or both ears.

Research Excerpts

ExcerptRelevanceReference
"This mouse model of tobramycin-induced ototoxicity is clinically relevant in that it results in an incidence and severity of hearing loss recently documented in clinic."8.02Ebselen attenuates tobramycin-induced ototoxicity in mice. ( Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021)
"This mouse model of tobramycin-induced ototoxicity is clinically relevant in that it results in an incidence and severity of hearing loss recently documented in clinic."4.02Ebselen attenuates tobramycin-induced ototoxicity in mice. ( Gu, R; Homan, J; Kil, J; Longenecker, RJ, 2021)
"Cisplatin ototoxicity has been associated with the generation of toxic levels of reactive oxygen species (ROS) which can lead to injury or loss of outer hair cells in the organ of Corti, damage to the stria vascularis, and loss of spiral ganglion cells, resulting in permanent hearing loss."1.33Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. ( Gu, R; Kil, J; Lynch, ED; Pierce, C, 2005)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (33.33)29.6817
2010's1 (33.33)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Gu, R2
Longenecker, RJ1
Homan, J1
Kil, J2
Lynch, ED1
Pierce, C1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Cystic Fibrosis (CF) Patients With Acute Pulmonary Exacerbation (APE) Receiving IV Tobramycin at Risk for Ototoxicity[NCT02819856]Phase 280 participants (Anticipated)Interventional2017-07-21Enrolling by invitation
Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift[NCT01444846]Phase 283 participants (Actual)Interventional2011-09-30Completed
Safety and Efficacy Study of SPI-1005 for Prevention of Chemotherapy Induced Hearing Loss[NCT01451853]Phase 280 participants (Anticipated)Interventional2018-01-15Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

3 other studies available for ebselen and Hearing Loss

ArticleYear
Ebselen attenuates tobramycin-induced ototoxicity in mice.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021, Volume: 20, Issue:2

    Topics: Animals; Evoked Potentials, Auditory, Brain Stem; Hair Cells, Auditory, Outer; Hearing Loss; Isoindo

2021
Ebselen could be used as anti-inflammatory Nox inhibitor.
    Future medicinal chemistry, 2012, Volume: 4, Issue:12

    Topics: Anti-Inflammatory Agents; Azoles; Catalytic Domain; Hearing Loss; Humans; Isoindoles; NADPH Oxidases

2012
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
    Hearing research, 2005, Volume: 201, Issue:1-2

    Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry,

2005
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
    Hearing research, 2005, Volume: 201, Issue:1-2

    Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry,

2005
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
    Hearing research, 2005, Volume: 201, Issue:1-2

    Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry,

2005
Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen.
    Hearing research, 2005, Volume: 201, Issue:1-2

    Topics: Administration, Oral; Allopurinol; Analysis of Variance; Animals; Antineoplastic Agents; Audiometry,

2005